CD5-directed CAR T-cell therapy has shown promising antitumor activity in systemic T-cell lymphomas, with overall response rates approaching 60 percent and manageable toxicity [8,9,10,11,12]. This evidence concerns the gene CD5 and T-cell non-Hodgkin lymphoma.